– USA, MD – YS Biopharma Co., Ltd. (Nasdaq: YS), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced the appointment of Dr. Yuntao Cui (JD), Dr. Jin Wang (PhD), Henry Chen, Haitao Zhao, Pierson Yue Pan, and Brenda Chunyuan Wu to its Board of Directors, effective February 13, 2024.
Concurrently, the Board has elected Dr. Ajit Shetty as Chair of the Board of Directors, effective February 13, 2024.
“We are pleased to welcome each of our new directors to the Board. Each of these talented individuals brings valuable expertise in various aspects of corporate governance, legal affairs, business management, and strategic decision-making. We expect that their diverse experience and commitment to success will serve our company well going forward.” said Board Chair, Dr. Ajit Shetty.
About Dr. Yuntao Cui
Dr. Yuntao Cui has over 15 years of law-related work experience and has previously worked as a Senior Lawyer at Zhong Lun Law Firm, one of the top law firms in China, and as General Manager of Legal Affairs at Wanda Group, a top conglomerate in the real estate, finance, and hospitality industries.
Dr. Cui is an SVP and General Counsel at Juventas Cell Therapy Ltd., a leading immune cell therapy company.
Dr. Cui holds a JD from Renmin University of China.
About Dr. Jin Wang
Dr. Jin Wang is the Founding Partner and CEO of Manhattan Capital Investment Consulting Group and has managed the venture capital investment fund Nuokang Venture Fund since 2014. Dr. Wang has more than 27 years of experience finding, building, and strategizing for biotech companies, including his co-founding and angel investment in leading medical professional networking and service firm DXY. Dr. Wang previously worked as an analyst and Asia/Greater China Regional Director for Paramount Capital Investment, LLC, and co-founded the Sino-American Pharmaceutical Professionals Association in 1993.
Dr. Wang holds a PhD in Biomedical Science from Worcester Polytechnic Institute.
About Henry Chen
Henry Chen is the CEO of Monument Pacific Development Corp., a California-based company dedicated to developing, managing, and operating residential and commercial properties in Northern and Southern California.
Mr. Chen received his MBA from the University of California, Berkeley’s Hass School of Business in 2012, and a Bachelor of Laws in Business Administration and Management from the Beijing University of Chemical Technology in 2005.
About Haitao Zhao
Haitao Zhao has served as a Partner of the Shanxi Tie Niu law firm since 2016, where he is responsible for handling corporate law related to intellectual property protection, corporate internal governance, and financing-related legal services. Previously, Mr. Zhao worked as an Attorney for the Beijing Ding En law firm from 2012-2016.
He holds an MA in International Law from Shanxi University.
About Pierson Yue
Pierson Yue Pan has served as a VP of Monument Pacific Development Corp. since 2018. Previously, Mr. Pan worked as VP of Project Development at real estate developer Propriis from 2012-2018, and as General Manager of the Africa Market with the China Civil Engineering Construction Company Nigeria Limited from 2004-2011.
Mr. Pan holds an MBA from the University of California, Berkeley’s Hass School of Business.
About Chunyuan (Brenda) Wu
Brenda Wu currently serves as the CFO of YS Group, a position she has held since December 31, 2020. Previously, Ms. Wu served as CFO of YS Group Biopharma from 2018-2020, and as Financial Controller for the same company from 2013-2018. Ms. Wu has also previously worked as a Senior Auditor at Ernst & Young.
Ms. Wu holds degrees in Accounting and Finance from Washington State University.
About YS Biopharma
YS Biopharma is a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a series of preventive and therapeutic biologics with a potential for improved Rabies, Coronavirus, Hepatitis B, Influenza, and Shingles vaccines. YS Biopharma operates in China, the United States, Singapore, and the Philippines, and is led by a management team that combines rich local expertise and global experience in the bio-pharmaceutical industry.
For more information: https://www.ysbiopharm.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
